World J Nephrol Urol

World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc

Journal website http://www.wjnu.org

Original Article

Volume 1, Number 1, February 2012, pages 16-22

Natriuretic Peptides’ Role in Determining the Chemotherapy-Induced Nephrotoxicity and Their Value in Follow-Up

**Table 1.** Demographic Characteristics of Patients, GFR, Natriuretic Peptides and Chemotherapeutic Drugs
Patient No	Age/Sex	Diagnosis	Course (Month)	Before the 1. Course	After the 4. Course	Total dose of
AML: acute myeloid leukemia; DLBCL: diffuse large b cell lymphoma; Ara-C: cytosine arabinoside; CMP: cyclophosphamide; ADR: doxorubicin; VCR: vincristine; PSN: prednisolone; RTX: rituximab; BLM: bleomycin; DTIC: dacarbazine; CDDP: cisplatin; DEX: dexamethasone; DTX: docetaxel; 5-FU: 5 fluorouracil; IFO: ifosfamide.
1	50/E	AML	4	118	15.56	26.47	84	24.70	51.70	Ara-C (72 gr)
2	53/E	AML	4	141	14.42	27.60	98	23.60	49.40	Ara-C (72 gr)
3	44/E	AML	4	128	12.89	25.82	96	26.90	45.20	Ara-C (72 gr)
4	44/K	AML	4	158	10.78	27.21	88	23.70	45.80	Ara-C (72 gr)
5	58/K	AML	4	95	14.50	29.80	26	27.90	49.80	Ara-C (72 gr)
6	20/K	AML	4	141	13.13	26.86	106	25.96	39.15	Ara-C (72 gr)
7	41/E	AML	4	121	14.41	28.47	77	24.99	42.50	Ara-C (72 gr)
8	21/E	AML	4	123	10.58	25.25	90	22.48	40.30	Ara-C (72 gr)
9	46/E	AML	4	158	13.36	26.15	100	24.87	49.60	Ara-C (72 gr)
10	29/E	Anaplastic Lymphoma	4	140	12.48	22.50	98	21.70	42.10	CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)
11	41/K	DLBCL	4	137	14.20	24.50	76	24.40	47.90	CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800mg)
12	39/E	Mantle Cell Lymphoma	4	120	15.80	25.10	76	25.10	49.20	CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)
13	79/E	DLBCL	4	64	15.89	31.23	48	28.98	51.85	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR(6.4mg), PSN(800mg)
14	34/K	DLBCL	4	122	13.39	26.60	72	26.40	47.60	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)
15	38/K	DLBCL	4	145	12.90	25.80	94	24.70	46.30	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)
16	72/K	DLBCL	4	122	15.74	30.80	65	28.10	50.70	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))
17	66/K	DLBCL	4	88	14.60	29.20	56	27.90	47.80	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))
18	77/K	DLBCL	4	87	15.60	31.80	55	26.40	49.60	RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))
19	28/E	Hodgkins Lymphoma, Mix Cell	4	211	11.10	25.40	133	23.40	45.80	ADR (200 mg), BLM (40 mg), VCR (6.4 mg), DTIC (1.4 gr)
20	24/E	Hodgkins Lymphoma, Nodular Scl.	4	179	11.12	24.60	96	24.80	50.50	ADR (200 mg), BLM (40 mg), VCR (6.4 mg), DTIC (1.4 gr)
21	52/E	Hodgkins Lymphoma, Nodular Scl	4	142	12.34	29.80	85	27.20	49.50	Ara-C (16 gr), CDDP (400 mg), DEX (100 mg)
22	38/K	Breast CA	4	151	13.32	27.40	96	25.80	45.20	CMP (2.4 gr), ADR (240 mg)
23	41/K	Thymoma	4	149	12.10	29.80	94	23.50	47.10	CMP (2 gr), ADR (240 mg), CDDP (360 mg), PSN (800 mg)
24	37/E	Gastric Adeno CA	4	171	14.30	28.40	95	25.60	43.40	DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)
25	45/E	Gastric Adeno CA	4	113	13.35	29.50	74	24.10	48.50	DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)
26	58/E	Lung CA	4	117	14.19	30.45	68	27.58	50.30	CDDP (240 mg), VNR (120 mg)
27	44/K	Cervix CA	4	111	11.20	29.70	82	26.70	44.60	CDDP (400 mg), 5-FU (3.85 gr)
28	66/E	Gastric Adeno CA	4	71	14.70	33.20	56	27.90	54.10	DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)
29	58/K	Angiosarcoma	4	105	13.10	32.80	71	26.20	52.70	IFO (8 gr), ADR (240 mg)
30	60/E	Sarcoma	4	126	15.54	32.40	80	27.20	62.40	IFO (8 gr), ADR (240 mg)

Table 1. Demographic Characteristics of Patients, GFR, Natriuretic Peptides and Chemotherapeutic Drugs

Patient No

Age/Sex

Diagnosis

Course (Month)

Before the 1. Course

After the 4. Course

Total dose of

Chemotherapeutic drug/m²

GFR ml/min/

BNP pg/ml

ANP pg/ml

GFR ml/min/

BNP pg/ml

ANP pg/ml

1.73m²

AML: acute myeloid leukemia; DLBCL: diffuse large b cell lymphoma; Ara-C: cytosine arabinoside; CMP: cyclophosphamide; ADR: doxorubicin; VCR: vincristine; PSN: prednisolone; RTX: rituximab; BLM: bleomycin; DTIC: dacarbazine; CDDP: cisplatin; DEX: dexamethasone; DTX: docetaxel; 5-FU: 5 fluorouracil; IFO: ifosfamide.

50/E

AML

118

15.56

26.47

24.70

51.70

Ara-C (72 gr)

53/E

AML

141

14.42

27.60

23.60

49.40

Ara-C (72 gr)

44/E

AML

128

12.89

25.82

26.90

45.20

Ara-C (72 gr)

44/K

AML

158

10.78

27.21

23.70

45.80

Ara-C (72 gr)

58/K

AML

14.50

29.80

27.90

49.80

Ara-C (72 gr)

20/K

AML

141

13.13

26.86

106

25.96

39.15

Ara-C (72 gr)

41/E

AML

121

14.41

28.47

24.99

42.50

Ara-C (72 gr)

21/E

AML

123

10.58

25.25

22.48

40.30

Ara-C (72 gr)

46/E

AML

158

13.36

26.15

100

24.87

49.60

Ara-C (72 gr)

29/E

Anaplastic Lymphoma

140

12.48

22.50

21.70

42.10

CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)

41/K

DLBCL

137

14.20

24.50

24.40

47.90

CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800mg)

39/E

Mantle Cell Lymphoma

120

15.80

25.10

49.20

CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)

79/E

DLBCL

15.89

31.23

28.98

51.85

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR(6.4mg), PSN(800mg)

34/K

DLBCL

122

13.39

26.60

26.40

47.60

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)

38/K

DLBCL

145

12.90

25.80

24.70

46.30

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg)

72/K

DLBCL

122

15.74

30.80

28.10

50.70

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))

66/K

DLBCL

14.60

29.20

27.90

47.80

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))

77/K

DLBCL

15.60

31.80

26.40

49.60

RTX (1.4 gr), CMP (3 gr), ADR (200 mg), VCR (6.4 mg), PSN (800 mg))

28/E

Hodgkins Lymphoma, Mix Cell

211

11.10

25.40

133

23.40

45.80

ADR (200 mg), BLM (40 mg), VCR (6.4 mg), DTIC (1.4 gr)

24/E

Hodgkins Lymphoma, Nodular Scl.

179

11.12

24.60

24.80

50.50

ADR (200 mg), BLM (40 mg), VCR (6.4 mg), DTIC (1.4 gr)

52/E

Hodgkins Lymphoma, Nodular Scl

142

12.34

29.80

27.20

49.50

Ara-C (16 gr), CDDP (400 mg), DEX (100 mg)

38/K

Breast CA

151

13.32

27.40

25.80

45.20

CMP (2.4 gr), ADR (240 mg)

41/K

Thymoma

149

12.10

29.80

23.50

47.10

CMP (2 gr), ADR (240 mg), CDDP (360 mg), PSN (800 mg)

37/E

Gastric Adeno CA

171

14.30

28.40

25.60

43.40

DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)

45/E

Gastric Adeno CA

113

13.35

29.50

24.10

48.50

DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)

58/E

Lung CA

117

14.19

30.45

27.58

50.30

CDDP (240 mg), VNR (120 mg)

44/K

Cervix CA

111

11.20

29.70

26.70

44.60

CDDP (400 mg), 5-FU (3.85 gr)

66/E

Gastric Adeno CA

14.70

33.20

27.90

54.10

DTX (300 mg), CDDP (300 mg), 5-FU (4 gr)

58/K

Angiosarcoma

105

13.10

32.80

26.20

52.70

IFO (8 gr), ADR (240 mg)

60/E

Sarcoma

126

15.54

32.40

27.20

62.40

IFO (8 gr), ADR (240 mg)

**Table 2.** The Relationship Between Plasma Natriuretic Peptides and Renal Function Tests According to Chemotherapy Courses
	Patients (n = 30)	Control group (n = 30)
NS:Non significant.
1. course before treatment (I)	13.5 ± 2.3	28.1 ± 4.2	128.5 ± 31.2	28.4 ± 2.5	13.7 ± 1.8	25.4 ± 3.3
1. course after treatment (II)	16.4 ± 2.7	30.9 ± 4.8	108.3 ± 31.7	121.1 ± 10.8	13.9 ± 2.1	24.8 ± 3.7
2. course before treatment (III)	15.5 ± 2.8	28.9 ± 3.5	114.3 ± 29.2	98.3 ± 12.3	14.0 ± 1.7	24.3 ± 2.6
2. course after treatment (IV)	19.0 ± 3.2	35.8 ± 4.5	97.6 ± 25.4	257.4 ± 34.6	13.8 ± 1.6	25.9 ± 2.8
3. course before treatment (V)	18.4 ± 2.9	32.3 ± 6.5	103.2 ± 26.7	148.2 ± 17.3	13.6 ± 1.8	25.3 ± 3.1
3. course after treatment (VI)	23.3 ± 3.2	40.5 ± 9.5	90.1 ± 24.1	382.6 ± 20.3	14.3 ± 2.2	24.9 ± 3.5
4. course before treatment (VII)	20.1 ± 2.1	34.3 ± 11.1	94.6 ± 26.4	325.4 ± 40.1	14.1 ± 1.5	24.6 ± 3.2
4. course after treatment (VIII)	25.6 ± 3.4	48 ± 16.9	81.2 ± 20.6	492.3 ± 62.4	14.5 ± 1.7	24.7 ± 3.8
ANOVA					NS	NS
F value	44.16	69.88	64.91	21.48	NS	NS
P value	< 0.001	< 0.001	< 0.001	< 0.001	NS	NS
TUKEY HSD	II,III,IV,V	II,III,IV,V	II,III,IV,V	II,III,IV,V	NS	NS
(comperison according to I)	VI,VII,VIII	VI,VII,VIII	VI,VII,VIII	VI,VII,VIII	NS	NS
P value	< 0.001	< 0.001	< 0.001	< 0.001	NS	NS

Table 2. The Relationship Between Plasma Natriuretic Peptides and Renal Function Tests According to Chemotherapy Courses

Patients (n = 30)

Control group (n = 30)

BNP (pg/ml)

ANP (pg/ml)

GFR (ml/min)

Pr/Cr (mg/dL)

BNP (pg/ml)

ANP (pg/ml)

NS:Non significant.

1. course before treatment (I)

13.5 ± 2.3

28.1 ± 4.2

128.5 ± 31.2

28.4 ± 2.5

13.7 ± 1.8

25.4 ± 3.3

1. course after treatment (II)

16.4 ± 2.7

30.9 ± 4.8

108.3 ± 31.7

121.1 ± 10.8

13.9 ± 2.1

24.8 ± 3.7

2. course before treatment (III)

15.5 ± 2.8

28.9 ± 3.5

114.3 ± 29.2

98.3 ± 12.3

14.0 ± 1.7

24.3 ± 2.6

2. course after treatment (IV)

19.0 ± 3.2

35.8 ± 4.5

97.6 ± 25.4

257.4 ± 34.6

13.8 ± 1.6

25.9 ± 2.8

3. course before treatment (V)

18.4 ± 2.9

32.3 ± 6.5

103.2 ± 26.7

148.2 ± 17.3

13.6 ± 1.8

25.3 ± 3.1

3. course after treatment (VI)

23.3 ± 3.2

40.5 ± 9.5

90.1 ± 24.1

382.6 ± 20.3

14.3 ± 2.2

24.9 ± 3.5

4. course before treatment (VII)

20.1 ± 2.1

34.3 ± 11.1

94.6 ± 26.4

325.4 ± 40.1

14.1 ± 1.5

24.6 ± 3.2

4. course after treatment (VIII)

25.6 ± 3.4

48 ± 16.9

81.2 ± 20.6

492.3 ± 62.4

14.5 ± 1.7

24.7 ± 3.8

ANOVA

F value

44.16

69.88

64.91

21.48

P value

< 0.001

TUKEY HSD

II,III,IV,V

(comperison according to I)

VI,VII,VIII

P value

< 0.001